salbutamol

Ligand id: 558

Name: salbutamol

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: salbutamol

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 4
Rotatable bonds 5
Topological polar surface area 72.72
Molecular weight 239.15
XLogP 1.17
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Highly selective β2-adrenoceptor agonist used in the treatment of COPD and asthma.
In April 2015, the FDA expanded approval to include treatment or prevention of bronchospasm in patients with reversible obstructive airway disease and for the treatment of exercise-induced bronchospasm (EIB).
Mechanism Of Action and Pharmacodynamic Effects
Agonism of β2-adrenergic receptors in the lungs results in smooth muscle relaxation of bronchial smooth muscle. This is believed to be through the mechanism of increased cAMP production via adenylate cyclase activation. Increased levels of cAMP increase activity levels of protein kinase A which inhibits phosphorylation of myosin and lowers intracellular calcium concentrations leading to smooth muscle relaxation and bronchodilation. Salbutamol also inhibits the release of bronchoconstricting agents from mast cells, enhances mucociliary clearance and inhibits microvascular leakage.
External links